# Harvard Bioscience Inc: financial statements, quarterly

HBIO · Nasdaq · CIK 1123494 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hbio.md) · [Financials](/companies/hbio/financials.md) · [Filings](/companies/hbio/filings.md) · [Insiders](/companies/hbio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hbio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [25.4](/filings/0001171843-24-006181.md) | [28.2 d](/filings/0001171843-25-001472.md) | [24.5](/filings/0001171843-25-003093.md) | [23.1](/filings/0001171843-25-005287.md) | [22.0](/filings/0001171843-25-007099.md) | [24.6 d](/filings/0001171843-26-001548.md) | [21.8](/filings/0001171843-26-003311.md) | [20.5](/filings/0001171843-26-005425.md) | [20.6](/filings/0001171843-25-007099.md) | [23.7 d](/filings/0001171843-26-001548.md) | [20.8](/filings/0001171843-26-003311.md) | [22.7](/filings/0001171843-26-005425.md) |
| Cost of revenue | $m | [10.6](/filings/0001171843-24-006181.md) | [11.8 d](/filings/0001171843-25-001472.md) | [9.7](/filings/0001171843-25-003093.md) | [9.9](/filings/0001171843-25-005287.md) | [9.2](/filings/0001171843-25-007099.md) | [10.5 d](/filings/0001171843-26-001548.md) | [9.6](/filings/0001171843-26-003311.md) | [8.9](/filings/0001171843-26-005425.md) | [8.6](/filings/0001171843-25-007099.md) | [9.6 d](/filings/0001171843-26-001548.md) | [8.5](/filings/0001171843-26-003311.md) | [10.1](/filings/0001171843-26-005425.md) |
| Gross profit | $m | [14.7](/filings/0001171843-24-006181.md) | [16.3 d](/filings/0001171843-25-001472.md) | [14.8](/filings/0001171843-25-003093.md) | [13.2](/filings/0001171843-25-005287.md) | [12.8](/filings/0001171843-25-007099.md) | [14.0 d](/filings/0001171843-26-001548.md) | [12.2](/filings/0001171843-26-003311.md) | [11.5](/filings/0001171843-26-005425.md) | [12.0](/filings/0001171843-25-007099.md) | [14.2 d](/filings/0001171843-26-001548.md) | [12.2](/filings/0001171843-26-003311.md) | [12.6](/filings/0001171843-26-005425.md) |
| Research and development | $m | [2.8](/filings/0001171843-24-006181.md) | [3.2 d](/filings/0001171843-25-001472.md) | [2.9](/filings/0001171843-25-003093.md) | [2.6](/filings/0001171843-25-005287.md) | [2.6](/filings/0001171843-25-007099.md) | [2.3 d](/filings/0001171843-26-001548.md) | [2.3](/filings/0001171843-26-003311.md) | [2.2](/filings/0001171843-26-005425.md) | [2.1](/filings/0001171843-25-007099.md) | [2.2 d](/filings/0001171843-26-001548.md) | [2.3](/filings/0001171843-26-003311.md) | [2.5](/filings/0001171843-26-005425.md) |
| Operating income | $m | [(0.9)](/filings/0001171843-24-006181.md) | [0.3 d](/filings/0001171843-25-001472.md) | [(2.3)](/filings/0001171843-25-003093.md) | [(2.1)](/filings/0001171843-25-005287.md) | [(1.9)](/filings/0001171843-25-007099.md) | [0.0 d](/filings/0001171843-26-001548.md) | [(49.7)](/filings/0001171843-26-003311.md) | [(0.8)](/filings/0001171843-26-005425.md) | [0.2](/filings/0001171843-25-007099.md) | [1.7 d](/filings/0001171843-26-001548.md) | [(1.2)](/filings/0001171843-26-003311.md) | [(1.0)](/filings/0001171843-26-005425.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.7](/filings/0001171843-24-006181.md) | [0.7 d](/filings/0001171843-25-001472.md) | [0.2](/filings/0001171843-25-003093.md) | [(0.4)](/filings/0001171843-25-005287.md) | [0.3](/filings/0001171843-25-007099.md) | [0.6 d](/filings/0001171843-26-001548.md) | [(0.5)](/filings/0001171843-26-003311.md) | [0.0](/filings/0001171843-26-005425.md) | [0.1](/filings/0001171843-25-007099.md) | [(0.4) d](/filings/0001171843-26-001548.md) | [0.1](/filings/0001171843-26-003311.md) | [0.0](/filings/0001171843-26-005425.md) |
| Net income | $m | [(1.2)](/filings/0001171843-24-006181.md) | [(1.8) d](/filings/0001171843-25-001472.md) | [(4.7)](/filings/0001171843-25-003093.md) | [(2.9)](/filings/0001171843-25-005287.md) | [(4.8)](/filings/0001171843-25-007099.md) | [0.0 d](/filings/0001171843-26-001548.md) | [(50.3)](/filings/0001171843-26-003311.md) | [(2.3)](/filings/0001171843-26-005425.md) | [(1.2)](/filings/0001171843-25-007099.md) | [(2.8) d](/filings/0001171843-26-001548.md) | [(3.4)](/filings/0001171843-26-003311.md) | [(2.9)](/filings/0001171843-26-005425.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001171843-24-006181.md) | not reported | [(0.11)](/filings/0001171843-25-003093.md) | [(0.07)](/filings/0001171843-25-005287.md) | [(0.11)](/filings/0001171843-25-007099.md) | not reported | [(11.42)](/filings/0001171843-26-003311.md) | [(0.52)](/filings/0001171843-26-005425.md) | [(0.03)](/filings/0001171843-25-007099.md) | not reported | [(0.77)](/filings/0001171843-26-003311.md) | [(0.64)](/filings/0001171843-26-005425.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001171843-24-006181.md) | not reported | [(0.11)](/filings/0001171843-25-003093.md) | [(0.07)](/filings/0001171843-25-005287.md) | [(0.11)](/filings/0001171843-25-007099.md) | not reported | [(11.42)](/filings/0001171843-26-003311.md) | [(0.52)](/filings/0001171843-26-005425.md) | [(0.03)](/filings/0001171843-25-007099.md) | not reported | [(0.77)](/filings/0001171843-26-003311.md) | [(0.64)](/filings/0001171843-26-005425.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.3](/filings/0001171843-23-006831.md) | [4.3](/filings/0001171843-25-001472.md) | [4.3](/filings/0001171843-24-002618.md) | [4.0](/filings/0001171843-24-004564.md) | [4.6](/filings/0001171843-24-006181.md) | [4.1](/filings/0001171843-26-001548.md) | [5.5](/filings/0001171843-25-003093.md) | [7.4](/filings/0001171843-25-005287.md) | [6.8](/filings/0001171843-25-007099.md) | [8.6](/filings/0001171843-26-005425.md) | [7.1](/filings/0001171843-26-003311.md) | [6.5](/filings/0001171843-26-005425.md) |
| Current assets | $m | [50.5](/filings/0001171843-23-006831.md) | [49.0](/filings/0001171843-25-001472.md) | [48.1](/filings/0001171843-24-002618.md) | [46.4](/filings/0001171843-24-004564.md) | [46.8](/filings/0001171843-24-006181.md) | [45.1](/filings/0001171843-26-001548.md) | [44.9](/filings/0001171843-25-003093.md) | [45.0](/filings/0001171843-25-005287.md) | [43.8](/filings/0001171843-25-007099.md) | [48.2](/filings/0001171843-26-005425.md) | [47.5](/filings/0001171843-26-003311.md) | [46.5](/filings/0001171843-26-005425.md) |
| Total assets | $m | [140](/filings/0001171843-23-006831.md) | [137](/filings/0001171843-25-001472.md) | [133](/filings/0001171843-24-002618.md) | [129](/filings/0001171843-24-004564.md) | [131](/filings/0001171843-24-006181.md) | [127](/filings/0001171843-26-001548.md) | [79.8](/filings/0001171843-25-003093.md) | [80.1](/filings/0001171843-25-005287.md) | [78.0](/filings/0001171843-25-007099.md) | [80.1](/filings/0001171843-26-005425.md) | [77.9](/filings/0001171843-26-003311.md) | [76.3](/filings/0001171843-26-005425.md) |
| Current liabilities | $m | [24.2](/filings/0001171843-23-006831.md) | [26.5](/filings/0001171843-25-001472.md) | [25.7](/filings/0001171843-24-002618.md) | [22.6](/filings/0001171843-24-004564.md) | [22.8](/filings/0001171843-24-006181.md) | [55.0](/filings/0001171843-26-001548.md) | [55.6](/filings/0001171843-25-003093.md) | [55.2](/filings/0001171843-25-005287.md) | [54.4](/filings/0001171843-25-007099.md) | [22.0](/filings/0001171843-26-005425.md) | [23.9](/filings/0001171843-26-003311.md) | [24.8](/filings/0001171843-26-005425.md) |
| Total liabilities | $m | [65.4](/filings/0001171843-23-006831.md) | [64.3](/filings/0001171843-25-001472.md) | [64.3](/filings/0001171843-24-002618.md) | [61.7](/filings/0001171843-24-004564.md) | [65.9](/filings/0001171843-24-006181.md) | [63.3](/filings/0001171843-26-001548.md) | [65.0](/filings/0001171843-25-003093.md) | [64.4](/filings/0001171843-25-005287.md) | [63.9](/filings/0001171843-25-007099.md) | [66.3](/filings/0001171843-26-005425.md) | [67.9](/filings/0001171843-26-003311.md) | [68.9](/filings/0001171843-26-005425.md) |
| Long-term debt | $m | [35.3](/filings/0001171843-23-006831.md) | [30.7](/filings/0001171843-25-001472.md) | [31.9](/filings/0001171843-24-002618.md) | [32.0](/filings/0001171843-24-004564.md) | [34.3](/filings/0001171843-24-006181.md) | [0.0](/filings/0001171843-26-001548.md) | [36.4](/filings/0001171843-25-003093.md) | [34.9](/filings/0001171843-25-005287.md) | [34.0](/filings/0001171843-25-007099.md) | [35.9](/filings/0001171843-26-005425.md) | [36.2](/filings/0001171843-26-003311.md) | [36.7](/filings/0001171843-26-005425.md) |
| Current portion of debt | $m | [3.8](/filings/0001171843-23-006831.md) | [6.1](/filings/0001171843-25-001472.md) | [4.0](/filings/0001171843-24-002618.md) | [4.0](/filings/0001171843-24-004564.md) | [4.0](/filings/0001171843-24-006181.md) | [37.0](/filings/0001171843-26-001548.md) | not reported | not reported | not reported | [0.0](/filings/0001171843-26-005425.md) | [0.0](/filings/0001171843-26-003311.md) | [0.0](/filings/0001171843-26-005425.md) |
| Shareholders' equity | $m | [74.3](/filings/0001171843-24-006181.md) | [73.1](/filings/0001171843-26-001548.md) | [68.8](/filings/0001171843-25-005287.md) | [67.2](/filings/0001171843-25-007099.md) | [65.3](/filings/0001171843-25-007099.md) | [63.3](/filings/0001171843-26-005425.md) | [14.8](/filings/0001171843-26-005425.md) | [15.7](/filings/0001171843-26-005425.md) | [14.1](/filings/0001171843-25-007099.md) | [13.7](/filings/0001171843-26-005425.md) | [10.0](/filings/0001171843-26-005425.md) | [7.4](/filings/0001171843-26-005425.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [4,361 d](/filings/0001171843-24-006181.md) | [4,303 d](/filings/0001171843-25-001472.md) | [1,403](/filings/0001171843-25-003093.md) | [(846) d](/filings/0001171843-25-005287.md) | [(842) d](/filings/0001171843-25-007099.md) | [1,725 d](/filings/0001171843-26-001548.md) | [2,986](/filings/0001171843-26-003311.md) | [2,755 d](/filings/0001171843-26-005425.md) | [1,084 d](/filings/0001171843-25-007099.md) | [(96.0) d](/filings/0001171843-26-001548.md) | [(662)](/filings/0001171843-26-003311.md) | [325 d](/filings/0001171843-26-005425.md) |
| Capital expenditure | $k | [217 d](/filings/0001171843-24-006181.md) | [830 d](/filings/0001171843-25-001472.md) | [645](/filings/0001171843-25-003093.md) | [818 d](/filings/0001171843-25-005287.md) | [880 d](/filings/0001171843-25-007099.md) | [301 d](/filings/0001171843-26-001548.md) | [513](/filings/0001171843-26-003311.md) | [89.0 d](/filings/0001171843-26-005425.md) | [207 d](/filings/0001171843-25-007099.md) | [449 d](/filings/0001171843-26-001548.md) | [426](/filings/0001171843-26-003311.md) | [688 d](/filings/0001171843-26-005425.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.6](/filings/0001171843-23-006831.md) | [42.8](/filings/0001171843-24-002618.md) | [42.4](/filings/0001171843-24-004564.md) | [42.7](/filings/0001171843-24-006181.md) | [43.4](/filings/0001171843-25-003093.md) | [43.5](/filings/0001171843-25-005287.md) | [43.6](/filings/0001171843-25-007099.md) | [4.4](/filings/0001171843-26-003311.md) | [4.4](/filings/0001171843-26-005425.md) | [44.6](/filings/0001171843-25-007099.md) | [4.5](/filings/0001171843-26-003311.md) | [4.5](/filings/0001171843-26-005425.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,552,305 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001171843-26-005425.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.